Company / SG&A per Share
SAB Biotherapeutics, Inc. SG&A per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$1.51
FY2025
5-year range
$0.26 / $3.25
FY2021-FY2025
Trend
-41.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $3.25 to $1.51 over the past 2 years.
Based on SEC 10-K filings.
1.51 in FY2025 with a 3-year CAGR of +31.8%.
Improved from $3.25 to $1.51 over the past 2 years.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +31.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, sg&a per share decreased 41.7% year-over-year.
- Peak sg&a per share was recorded in FY2023.
- Lowest sg&a per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.51 | -41.7% |
| FY2024 | $2.58 | -20.6% |
| FY2023 | $3.25 | +394.1% |
| FY2022 | $0.66 | +152.3% |
| FY2021 | $0.26 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026